Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Drug Resistance, Neoplasm
  • Lung Neoplasms
  • Mutation
  • Receptor, Epidermal Growth Factor

abstract

  • Among patients with acquired resistance to EGFR TKIs, the presence of T790M defines a clinical subset with a relatively favorable prognosis and more indolent progression. Knowledge of T790M status is therefore important both for the clinical care of these patients and for the optimal design and interpretation of clinical trials in this setting.

publication date

  • March 15, 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3060283

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-10-2692

PubMed ID

  • 21135146

Additional Document Info

start page

  • 1616

end page

  • 22

volume

  • 17

number

  • 6